📋 Tender Overview
Contract awarded for Centralized framework agreement for 24 months for the supply of medicines iii/2026 { "detected_language": "romanian", "translated_text": "lot-0069, title: codeine phosphate lph 15 mg ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications document. according to the specifications document, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications document - chapter 9. lot-0081, title: dexketoprofen 50 mg/2 ml ®, tador ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications document. according to the specifications document, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications document - chapter 9. lot-0104, title: clexane 4000 ui (40 mg)/ 0.4 ml or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications document. according to the specifications document, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications document - chapter 9. lot-0107, title: clexane 6000 ui (60 mg)/ 0.6 ml or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications document. according to the specifications document, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications document - chapter 9. lot-0114, title: esomeprazole -40mg- powder for solution injection/perfusion or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications document. according to the specifications document, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications document - chapter 9. lot-0192, title: lornoxicam 8 mg/2 ml ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications document. according to the specifications document, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications document - chapter 9. lot-0201, title: meloxicam rompharm 15 mg/1.5 ml ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications document. according to the specifications document, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications document - chapter 9. lot-0214, title: betaloc 5mg/5ml or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications document. according to the specifications document, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications document - chapter 9. lot-0248, title: controloc 40 mg, pantoprazole sun 40 mg, zencopan 40 mg ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications document. according to the specifications document, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications document - chapter 9. lot-0313, title: tobrom ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications document. according to the specifications document, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications document - chapter 9. lot-0317, title: dexatobrom sol. oft. ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications document. according to the specifications document, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications document - chapter 9. lot-0355, title: gadovist 1.0mmol/ml or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found estimated value excluding vat: 1593600.00 ron.Centralized framework agreement for 24 months for the supply of medicines iii/2026
